Dr. Reddy’s Laboratories has entered into an agreement with pharma giant Novartis AG to acquire cardiovascular brand Cidmus in India for $61 million.

Under the agreement, it will be assigned and transferred the Cidmus trademark in India from Novartis AG. Cidmus sales in the country was around ₹136.4 crore for the most recent 12 months ending in February 2022, Dr. Reddy’s said on April 1, citing IQVIA MAT numbers.

The Cidmus brand will be affixed on the pharmaceutical composition comprising a combination of Valsartan and Sacubitril (currently under Novartis patent) which is indicated for heart failure patients with reduced ejection fraction. The tablets were available in three strengths, the company said.

source/content: thehindu.com (edited)